<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Res Med Sci</journal-id><journal-id journal-id-type="publisher-id">JRMS</journal-id><journal-title-group><journal-title>Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1735-1995</issn><issn pub-type="epub">1735-7136</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22973366</article-id><article-id pub-id-type="pmc">3434899</article-id><article-id pub-id-type="publisher-id">JRMS-16-1578</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Iraji</surname><given-names>Fariba</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Faghihi</surname><given-names>Gita</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Asilian</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Siadat</surname><given-names>Amir Hossein</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Larijani</surname><given-names>Fatemeh Taghavi</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Akbari</surname><given-names>Mojtaba</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1-</label>Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.</aff><aff id="aff2"><label>2-</label>Associate Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.</aff><aff id="aff3"><label>3-</label>Assistant Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.</aff><aff id="aff4"><label>4-</label>Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.</aff><aff id="aff5"><label>5-</label>Epidemiologist, Department of Health, Isfahan University of Medical Sciences, Isfahan, Iran.</aff><author-notes><corresp id="cor1">
Corresponding author: Amir Hossein Siadat E-mail: <email xlink:href="amirhossein1@yahoo.com">amirhossein1@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2011</year></pub-date><volume>16</volume><issue>12</issue><fpage>1578</fpage><lpage>1582</lpage><history><date date-type="received"><day>10</day><month>7</month><year>2011</year></date><date date-type="accepted"><day>05</day><month>12</month><year>2011</year></date></history><permissions><copyright-statement>Copyright: © Journal of Research in Medical Sciences</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="4069" xml_f="4080" txt_i="11" txt_f="22">BACKGROUND:</offsets></title><p><offsets xml_i="4091" xml_f="4750" txt_i="23" txt_f="682">Lichen planus is recognized as an inflammatory disease of the skin with different morphologic patterns. Different treatment modalities, including topical and systemic corticosteroids, methotrexate, cyclosporine, azathioprine, topical calcineurin inhibitors, and psoralen plus UVA (PUVA), have been suggested for lichen planus. Although the efficacy of narrowband UVB (NBUVB) for treatment of lichen planus has been shown, no randomized clinical trial has compared NBUVB versus systemic corticosteroids for treatment of the disease. In the current study, we evaluated the efficacy of NBUVB versus systemic corticosteroids in the treatment of the lichen planus.</offsets></p></sec><sec id="st2"><title><offsets xml_i="4781" xml_f="4789" txt_i="684" txt_f="692">METHODS:</offsets></title><p><offsets xml_i="4800" xml_f="5342" txt_i="693" txt_f="1235">Forty-six patients with confirmed diagnosis of lichen planus were randomly selected. The subjects were randomized into two groups of 23 to be treated with either systemic corticosteroids or NBUVB. All of the selected cases had generalized lichen planus that involved at least 20% of the body area and their pruritus was resistant to antihistamine drugs. Patients in the systemic corticosteroids group were treated with prednisolon 0.3 mg/kg for 6 weeks. NBUVB was performed three times a week for 6 weeks. The maximum dose of NBUVB was 9 J/cm</offsets><sup><offsets xml_i="5347" xml_f="5348" txt_i="1235" txt_f="1236">2</offsets></sup><offsets xml_i="5354" xml_f="5477" txt_i="1236" txt_f="1359">. Data regarding demographic characteristics of the patients was also collected. All collected data was analyzed using SPSS</offsets><sub><offsets xml_i="5482" xml_f="5484" txt_i="1359" txt_f="1361">15</offsets></sub><offsets xml_i="5490" xml_f="5576" txt_i="1361" txt_f="1447"> and statistical tests including analysis of variance (ANOVA), chi-square, and t-test.</offsets></p></sec><sec id="st3"><title><offsets xml_i="5607" xml_f="5615" txt_i="1449" txt_f="1457">RESULTS:</offsets></title><p><offsets xml_i="5626" xml_f="6135" txt_i="1458" txt_f="1967">46 patients (23 patients in systemic steroid group and 23 patients in NBUVB group) were evaluated. There was a significant difference between the 2 groups regarding the efficacy of the treatment. According to chi-square test, NBUVB was significantly more effective than systemic steroid in treatment of generalized lichen planus (p = 0.008). According to the results, patient satisfaction was also significantly higher in the group treated with NBUVB as compared with the systemic corticosteroids (p = 0.012).</offsets></p></sec><sec id="st4"><title><offsets xml_i="6166" xml_f="6178" txt_i="1969" txt_f="1981">CONCLUSIONS:</offsets></title><p><offsets xml_i="6189" xml_f="6486" txt_i="1982" txt_f="2279">Overall, the results of our study and other previous studies showed that NBUVB may be regarded as an effective treatment for generalized cutaneous lichen planus. This treatment may be especially utilized when there is contraindication for systemic corticosteroids or other immunosuppressive drugs.</offsets></p></sec></abstract><kwd-group><title>KEYWORDS:</title><kwd>Lichen Planus</kwd><kwd>Narrowband UVB</kwd><kwd>Systemic Corticosteroids</kwd></kwd-group></article-meta></front><body><p><offsets xml_i="6670" xml_f="6773" txt_i="2288" txt_f="2391">Lichen planus is recognized as an inflammatory disease of the skin with different morphologic patterns.</offsets><xref ref-type="bibr" rid="ref1"><offsets xml_i="6806" xml_f="6807" txt_i="2391" txt_f="2392">1</offsets></xref><offsets xml_i="6814" xml_f="6912" txt_i="2392" txt_f="2490"> Its exact prevalence is not known but estimated to be found among 0.2-1% of the adult population.</offsets><xref ref-type="bibr" rid="ref1"><offsets xml_i="6945" xml_f="6946" txt_i="2490" txt_f="2491">1</offsets></xref><offsets xml_i="6953" xml_f="7044" txt_i="2491" txt_f="2582"> The diagnosis of lichen planus is based on clinical findings and histological examination.</offsets><xref ref-type="bibr" rid="ref1"><offsets xml_i="7077" xml_f="7078" txt_i="2582" txt_f="2583">1</offsets></xref><offsets xml_i="7085" xml_f="7304" txt_i="2583" txt_f="2802"> Different treatment modalities have been suggested for the disease including topical and systemic corticosteroids, methotrexate, cyclosporine, azathioprine, topical calcineurin inhibitors, and psoralen plus UVA (PUVA).</offsets><xref ref-type="bibr" rid="ref2"><offsets xml_i="7337" xml_f="7338" txt_i="2802" txt_f="2803">2</offsets></xref></p><p><offsets xml_i="7352" xml_f="7496" txt_i="2804" txt_f="2948">As lichen planus is recognized as an immunologic disorder, phototherapy can be regarded as an effective alternative treatment for this disorder.</offsets><xref ref-type="bibr" rid="ref3"><offsets xml_i="7529" xml_f="7530" txt_i="2948" txt_f="2949">3</offsets></xref><offsets xml_i="7537" xml_f="7538" txt_i="2949" txt_f="2950">–</offsets><xref ref-type="bibr" rid="ref5"><offsets xml_i="7571" xml_f="7572" txt_i="2950" txt_f="2951">5</offsets></xref><offsets xml_i="7579" xml_f="7721" txt_i="2951" txt_f="3093"> In narrow band UVB (NBUVB) therapy, fluorescent tubes emitting NBUVB in the range of 310-315 nm with the maximum emission at 312 nm are used.</offsets><xref ref-type="bibr" rid="ref6"><offsets xml_i="7754" xml_f="7755" txt_i="3093" txt_f="3094">6</offsets></xref><offsets xml_i="7762" xml_f="7979" txt_i="3094" txt_f="3311"> NBUVB reduces langerhans cells and induces the production and secretion of the cytokines and neuropeptides. It can also induce anti-inflammatory effects through Intercellular Adhesion Molecule 1 (ICAM-1) suppression.</offsets><xref ref-type="bibr" rid="ref5"><offsets xml_i="8012" xml_f="8013" txt_i="3311" txt_f="3312">5</offsets></xref><offsets xml_i="8020" xml_f="8130" txt_i="3312" txt_f="3422"> NBUVB is the first available light source with the advantage of selective wave length and fewer side effects.</offsets><xref ref-type="bibr" rid="ref7"><offsets xml_i="8163" xml_f="8164" txt_i="3422" txt_f="3423">7</offsets></xref><offsets xml_i="8171" xml_f="8248" txt_i="3423" txt_f="3500"> Therefore, this method can be used safely in pregnant patients and children.</offsets><xref ref-type="bibr" rid="ref8"><offsets xml_i="8281" xml_f="8282" txt_i="3500" txt_f="3501">8</offsets></xref></p><p><offsets xml_i="8296" xml_f="8415" txt_i="3502" txt_f="3621">In contrast to PUVA therapy, there is no need for eye protection after NBUVB and the cost of treatment will be reduced.</offsets><xref ref-type="bibr" rid="ref5"><offsets xml_i="8448" xml_f="8449" txt_i="3621" txt_f="3622">5</offsets></xref><offsets xml_i="8456" xml_f="8595" txt_i="3622" txt_f="3761"> In addition, compared to PUVA, NBUVB is associated with less risk of side effects including non-melanoma skin cancers and premature aging.</offsets><xref ref-type="bibr" rid="ref7"><offsets xml_i="8628" xml_f="8629" txt_i="3761" txt_f="3762">7</offsets></xref></p><p><offsets xml_i="8643" xml_f="8952" txt_i="3763" txt_f="4072">Although the efficacy of NBUVB for treatment of lichen planus has been shown, no randomized clinical trial has compare NBUVB versus systemic corticosteroids for treatment of the disease. Thus, the current study evaluated the efficacy of NBUVB versus systemic corticosteroids in the treatment of lichen planus.</offsets></p><sec sec-type="methods" id="sec1-1"><title><offsets xml_i="8999" xml_f="9006" txt_i="4073" txt_f="4080">Methods</offsets></title><p><offsets xml_i="9017" xml_f="9205" txt_i="4081" txt_f="4269">This study was performed during 2008-2010 in Alzahra Hospital, Khorshid Hospital and Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.</offsets></p><p><offsets xml_i="9212" xml_f="9375" txt_i="4270" txt_f="4433">Ethics committee clearance was achieved and informed consents were obtained from all patients (Isfahan University of Medical Sciences registration number: 385413).</offsets></p><p><offsets xml_i="9382" xml_f="9929" txt_i="4434" txt_f="4981">A total number of 46 patients with confirmed diagnosis of lichen planus were randomly selected. They were randomized using simple randomization to be treated either with systemic corticosteroids or NBUVB. The diagnosis of lichen planus was confirmed by biopsy. All selected cases had generalized lichen planus that involved at least 20% of the body area and their pruritus had been resistant to antihistamine drugs for 2 weeks. Patients with erosive oral lichen planus, severe nail involvement and lichen planopilaris were excluded from the study.</offsets></p><p><offsets xml_i="9936" xml_f="10164" txt_i="4982" txt_f="5210">For performing NBUVB, Fitzpatrick skin type was determined for each patient. After selecting minimal erythema dose (MED), NBUVB was performed three times a week at 70% of the MED for 6 weeks. The maximum dose of NBUVB was 9 j/cm</offsets><sup><offsets xml_i="10169" xml_f="10170" txt_i="5210" txt_f="5211">2</offsets></sup><offsets xml_i="10176" xml_f="10177" txt_i="5211" txt_f="5212">.</offsets><xref ref-type="bibr" rid="ref9"><offsets xml_i="10210" xml_f="10211" txt_i="5212" txt_f="5213">9</offsets></xref><offsets xml_i="10218" xml_f="10337" txt_i="5213" txt_f="5332"> On the other hand, patients in the systemic corticosteroids group were treated with prednisolon 0.3 mg/kg for 6 weeks.</offsets></p><p><offsets xml_i="10344" xml_f="10544" txt_i="5333" txt_f="5533">The severity of pruritus was determined using a visual analogue scale (VAS) with a range of 0-10. Moreover, the severity of elevation and erythema were assessed by the investigator and were rated 0-4.</offsets></p><p><offsets xml_i="10551" xml_f="10905" txt_i="5534" txt_f="5888">At the end of the study, according to the response of the lesions to treatment (elimination of the pruritus, elevation and erythema of the lesions), patients were classified into 4 groups. Groups 1-4 included patients with complete response (more than 90%), partial response (50-90%), weak response (20-50%) and no response (less than 20%), respectively.</offsets></p><p><offsets xml_i="10912" xml_f="11139" txt_i="5889" txt_f="6116">Patient satisfaction with improvement of the lesions was assessed using a 10-point (0-10) VAS in which 0-5 indicated poor and moderate response, 6-7 indicated good and very good response and 8-10 represented excellent response.</offsets></p><p><offsets xml_i="11146" xml_f="11436" txt_i="6117" txt_f="6407">Data regarding demographic characteristics of the patients was also collected. Collected data was analyzed using statistical tests including t-test and analysis of variance (ANOVA) for quantitative variables and chi-square test for qualitative variables. All analyses were performed by SPSS</offsets><sub><offsets xml_i="11441" xml_f="11443" txt_i="6407" txt_f="6409">15</offsets></sub><offsets xml_i="11449" xml_f="11507" txt_i="6409" txt_f="6464">. The level of significance was set at 0.05 (p &lt; 0.05).</offsets></p></sec><sec sec-type="results" id="sec1-2"><title><offsets xml_i="11560" xml_f="11567" txt_i="6466" txt_f="6473">Results</offsets></title><p><offsets xml_i="11578" xml_f="11852" txt_i="6474" txt_f="6748">Overall, 46 patients (23 patients in each group) were evaluated. The mean age of patients in the systemic corticosteroids and NBUVB groups were 42.04 ± 2.46 and 36.13 ± 2.88, respectively. There was no significant difference regarding age between the two groups (p = 0.109).</offsets></p><p><offsets xml_i="11859" xml_f="11985" txt_i="6749" txt_f="6875">There was no significant association between sex and duration of the disease (p = 0.763 for females and p = 0.738 for males) (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="12017" xml_f="12024" txt_i="6875" txt_f="6882">Table 1</offsets></xref><offsets xml_i="12031" xml_f="12033" txt_i="6882" txt_f="6884">).</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="12081" xml_f="12088" txt_i="6885" txt_f="6892">Table 1</offsets></label><caption><p><offsets xml_i="12108" xml_f="12168" txt_i="6892" txt_f="6952">Mean of disease duration in the two groups separated by sex.</offsets></p></caption><graphic xlink:href="JRMS-16-1578-g001"></graphic></table-wrap><p><offsets xml_i="12248" xml_f="12409" txt_i="6953" txt_f="7114">In addition, before initiation of the treatment, ANOVA did not show significant differences regarding duration of the disease between the two groups (p = 0.910).</offsets></p><p><offsets xml_i="12416" xml_f="12646" txt_i="7115" txt_f="7345">There was a significant difference in efficacy of treatment between the two groups. According to chi-square test, NBUVB was significantly more effective than systemic steroid in treatment of generalized lichen planus (p = 0.008) (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="12678" xml_f="12685" txt_i="7345" txt_f="7352">Table 2</offsets></xref><offsets xml_i="12692" xml_f="12694" txt_i="7352" txt_f="7354">).</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="12742" xml_f="12749" txt_i="7355" txt_f="7362">Table 2</offsets></label><caption><p><offsets xml_i="12769" xml_f="12866" txt_i="7362" txt_f="7459">The prevalence distribution of the response to treatment in the systemic steroid and NBUVB groups</offsets></p></caption><graphic xlink:href="JRMS-16-1578-g002"></graphic></table-wrap><p><offsets xml_i="12946" xml_f="13088" txt_i="7460" txt_f="7602">Patient satisfaction was also significantly higher in the group treated with NBUVB as compared with the systemic corticosteroids (p = 0.012) (</offsets><xref ref-type="table" rid="T3"><offsets xml_i="13120" xml_f="13127" txt_i="7602" txt_f="7609">Table 3</offsets></xref><offsets xml_i="13134" xml_f="13195" txt_i="7609" txt_f="7670">). No significant side effects were observed in either group.</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="13243" xml_f="13250" txt_i="7671" txt_f="7678">Table 3</offsets></label><caption><p><offsets xml_i="13270" xml_f="13392" txt_i="7678" txt_f="7800">The prevalence distribution of the response to treatment as rated by the patients in the systemic steroid and NBUVB groups</offsets></p></caption><graphic xlink:href="JRMS-16-1578-g003"></graphic></table-wrap></sec><sec sec-type="discussion" id="sec1-3"><title><offsets xml_i="13521" xml_f="13531" txt_i="7802" txt_f="7812">Discussion</offsets></title><p><offsets xml_i="13542" xml_f="13662" txt_i="7813" txt_f="7933">Corticosteroids have been used widely for a range of inflammatory and immune mediated disorders in the last fifty years.</offsets><xref ref-type="bibr" rid="ref10"><offsets xml_i="13696" xml_f="13698" txt_i="7933" txt_f="7935">10</offsets></xref><offsets xml_i="13705" xml_f="14139" txt_i="7935" txt_f="8369"> On the other hand, NBUVB radiation induces less erythema and carcinogenicity with lower cumulative doses than PUVA while the treatment response remains high. In the current study, we evaluated two different methods (NBUVB versus systemic corticosteroids) in the treatment of the lichen planus. Our results showed that NBUVB was significantly more effective than systemic corticosteroids in the treatment of generalized lichen planus.</offsets></p><p><offsets xml_i="14146" xml_f="14357" txt_i="8370" txt_f="8581">Saricaoğlu et al. evaluated the efficacy of NBUVB in the treatment of 10 patients with lichen planus. They reported that five patients responded completely and four were partially responsive at the end of the 30</offsets><sup><offsets xml_i="14362" xml_f="14364" txt_i="8581" txt_f="8583">th</offsets></sup><offsets xml_i="14370" xml_f="14456" txt_i="8583" txt_f="8669"> session. Moreover, 3 of the partially responsive cases responded completely at the 31</offsets><sup><offsets xml_i="14461" xml_f="14463" txt_i="8669" txt_f="8671">st</offsets></sup><offsets xml_i="14469" xml_f="14473" txt_i="8671" txt_f="8675">, 36</offsets><sup><offsets xml_i="14478" xml_f="14480" txt_i="8675" txt_f="8677">th</offsets></sup><offsets xml_i="14486" xml_f="14493" txt_i="8677" txt_f="8684"> and 51</offsets><sup><offsets xml_i="14498" xml_f="14500" txt_i="8684" txt_f="8686">st</offsets></sup><offsets xml_i="14506" xml_f="14635" txt_i="8686" txt_f="8815"> sessions, respectively. The authors suggested NBUVB as an inevitable treatment alternative for resistant cases of lichen planus.</offsets><xref ref-type="bibr" rid="ref5"><offsets xml_i="14668" xml_f="14669" txt_i="8815" txt_f="8816">5</offsets></xref></p><p><offsets xml_i="14683" xml_f="15253" txt_i="8817" txt_f="9387">In another study, Habib et al. evaluated the efficacy of BUVB for the treatment of widespread lichen planus in a retrospective study among 20 patients. NBUVB was applied thrice a week. They considered 4 types of response including complete response, partial response, poor response and failure. Their results showed that complete and partial responses were obtained in 11 and 4 patients, respectively. Response was obtained with a median delay of 3 months (ranging: 2-6 months) following a median of 30 sessions (12 to 50) and an accumulated dose of UVB of 36 ± 4.8 j/cm</offsets><sup><offsets xml_i="15258" xml_f="15259" txt_i="9387" txt_f="9388">2</offsets></sup><offsets xml_i="15265" xml_f="15351" txt_i="9388" txt_f="9474">. The authors highlighted the positive effect of NBUVB for treatment of lichen planus.</offsets><xref ref-type="bibr" rid="ref9"><offsets xml_i="15384" xml_f="15385" txt_i="9474" txt_f="9475">9</offsets></xref></p><p><offsets xml_i="15399" xml_f="16113" txt_i="9476" txt_f="10190">In a retrospective study by Pavlotsky et al. the efficacy of UVB (narrow band or broad band) for treatment of generalized lichen planus in 50 patients was evaluated. They treated 7 and 43 patients by broad and narrow band UVB, respectively. According to their results, while complete response was achieved in 70% of the patients, 85% of those were still in remission after a median of 34.7 months. The complete response rate and the need for higher cumulative exposure doses were not affected by sex, age, skin type, presence of additional diseases, failure of previous treatment or disease duration. The authors concluded that UVB was a safe and effective treatment option for generalized cutaneous lichen planus.</offsets><xref ref-type="bibr" rid="ref11"><offsets xml_i="16147" xml_f="16149" txt_i="10190" txt_f="10192">11</offsets></xref></p><p><offsets xml_i="16163" xml_f="16455" txt_i="10193" txt_f="10485">Overall, the results of our study and previous research showed that NBUVB may be regarded as an effective treatment for generalized cutaneous lichen planus. This treatment may be especially regarded when there is contraindication for systemic corticosteroids or other immunosuppressive drugs.</offsets></p><p><offsets xml_i="16462" xml_f="16642" txt_i="10486" txt_f="10666">We observed no significant side effects in either group. Therefore, NBUVB can be suggested as an ideal alternative for systemic steroids in patients with generalized lichen planus.</offsets></p><p><offsets xml_i="16649" xml_f="16888" txt_i="10667" txt_f="10906">According to the literature, our study is the first randomized, controlled, clinical trial that evaluated the efficacy of NBUVB for treatment of lichen planus. More studies are recommended to better evaluate the efficacy of this treatment.</offsets></p></sec><sec id="sec1-4"><title><offsets xml_i="16922" xml_f="16944" txt_i="10908" txt_f="10930">Authors’ Contributions</offsets></title><p><offsets xml_i="16955" xml_f="17138" txt_i="10931" txt_f="11114">FI, GF, AA, and AHS provided the idea, performed the research, and prepared the manuscript. FTL and MA performed the research. All authors have read and approved the final manuscript.</offsets></p></sec></body><back><fn-group><fn fn-type="conflict"><p><bold>Conflict of Interests</bold> Authors have no conflict of interests.</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shiohara</surname><given-names>T</given-names></name><name><surname>Kano</surname><given-names>Y</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Bolognia</surname><given-names>JL</given-names></name><name><surname>Jorizzo</surname><given-names>JL</given-names></name><name><surname>Rapini</surname><given-names>RP</given-names></name></person-group><article-title>Lichen planus and lichenoid dermatoses</article-title><source>Dermatology</source><year>2008</year><edition>2nd ed</edition><publisher-loc>New York</publisher-loc><publisher-name>Mosby</publisher-name><fpage>159</fpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cribier</surname><given-names>B</given-names></name><name><surname>Frances</surname><given-names>C</given-names></name><name><surname>Chosidow</surname><given-names>O</given-names></name></person-group><article-title>Treatment of lichen planus.An evidence-based medicine analysis of efficacy</article-title><source>Arch Dermatol</source><year>1998</year><volume>134</volume><issue>12</issue><fpage>1521</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">9875189</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wackernagel</surname><given-names>A</given-names></name><name><surname>Legat</surname><given-names>FJ</given-names></name><name><surname>Hofer</surname><given-names>A</given-names></name><name><surname>Quehenberger</surname><given-names>F</given-names></name><name><surname>Kerl</surname><given-names>H</given-names></name><name><surname>Wolf</surname><given-names>P</given-names></name></person-group><article-title>Psoralen plus UVA vs.UVB-311 nm for the treatment of lichen planus</article-title><source>Photodermatol Photoimmunol Photomed</source><year>2007</year><volume>23</volume><issue>1</issue><fpage>15</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17254030</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taneja</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>CR</given-names></name></person-group><article-title>Narrow-band UVB for lichen planus treatment</article-title><source>Int J Dermatol</source><year>2002</year><volume>41</volume><issue>5</issue><fpage>282</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12100704</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saricaoglu</surname><given-names>H</given-names></name><name><surname>Karadogan</surname><given-names>SK</given-names></name><name><surname>Baskan</surname><given-names>EB</given-names></name><name><surname>Tunali</surname><given-names>S</given-names></name></person-group><article-title>Narrowband UVB therapy in the treatment of lichen planus</article-title><source>Photodermatol Photoimmunol Photomed</source><year>2003</year><volume>19</volume><issue>5</issue><fpage>265</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">14535898</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogra</surname><given-names>S</given-names></name><name><surname>Kanwar</surname><given-names>AJ</given-names></name></person-group><article-title>Narrow band UVB phototherapy in dermatology</article-title><source>Indian J Dermatol Venereol Leprol</source><year>2004</year><volume>70</volume><issue>4</issue><fpage>205</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17642615</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snellman</surname><given-names>E</given-names></name><name><surname>Klimenko</surname><given-names>T</given-names></name><name><surname>Rantanen</surname><given-names>T</given-names></name></person-group><article-title>Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis</article-title><source>Acta Derm Venereol</source><year>2004</year><volume>84</volume><issue>2</issue><fpage>132</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15206693</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tauscher</surname><given-names>AE</given-names></name><name><surname>Fleischer</surname><given-names>AB</given-names><suffix>Jr</suffix></name><name><surname>Phelps</surname><given-names>KC</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name></person-group><article-title>Psoriasis and pregnancy</article-title><source>J Cutan Med Surg</source><year>2002</year><volume>6</volume><issue>6</issue><fpage>561</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">12362257</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>F</given-names></name><name><surname>Stoebner</surname><given-names>PE</given-names></name><name><surname>Picot</surname><given-names>E</given-names></name><name><surname>Peyron</surname><given-names>JL</given-names></name><name><surname>Meynadier</surname><given-names>J</given-names></name><name><surname>Meunier</surname><given-names>L</given-names></name></person-group><article-title>[Narrow band UVB phototherapy in the treatment of widespread lichen planus]</article-title><source>Ann Dermatol Venereol</source><year>2005</year><volume>132</volume><issue>1</issue><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15746601</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghabanchi</surname><given-names>J</given-names></name><name><surname>Bahri Najafi</surname><given-names>R</given-names></name><name><surname>Haghnegahdar</surname><given-names>S</given-names></name></person-group><article-title>Treatment of oral inflammatory diseases with a new mucoadhesive prednisolone tablet versus triamcinolone acetonide paste</article-title><source>IRCMJ</source><year>2009</year><volume>11</volume><issue>2</issue><fpage>155</fpage><lpage>9</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlotsky</surname><given-names>F</given-names></name><name><surname>Nathansohn</surname><given-names>N</given-names></name><name><surname>Kriger</surname><given-names>G</given-names></name><name><surname>Shpiro</surname><given-names>D</given-names></name><name><surname>Trau</surname><given-names>H</given-names></name></person-group><article-title>Ultraviolet-B treatment for cutaneous lichen planus: our experience with 50 patients</article-title><source>Photodermatol Photoimmunol Photomed</source><year>2008</year><volume>24</volume><issue>2</issue><fpage>83</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18353088</pub-id></element-citation></ref></ref-list></back></article>